Total (n=877) | HIC-hot (n=622, 70.9%) | HIC-cold (n=255, 29.1%) | P value | |
Age | ||||
Mean (SD) | 68.0 (10.2) | 68.4 (10.3) | 67.0 (10.0) | 0.070 |
Median (range) | 67.6 (35.2–95.1) | 68.1 (35.2–92.9) | 66.5 (36.5–95.1) | 0.075 |
Gender, n (%) | 0.004 | |||
Female | 382 (43.6) | 290 (46.6) | 92 (36.1) | |
Male | 495 (56.4) | 332 (53.4) | 163 (63.9) | |
Histology, n (%) | <0.001 | |||
Adenocarcinoma | 573 (65.3) | 430 (69.1) | 143 (56.1) | |
Squamous | 188 (21.4) | 116 (18.6) | 72 (28.2) | |
NSCLC other | 116 (13.2) | 76 (12.2) | 40 (15.7) | |
Disease stage at study entry, n (%) | 0.739 | |||
Stage IIIB | 112 (12.8) | 78 (12.5) | 34 (13.3) | |
Stage IV | 765 (87.2) | 544 (87.5) | 221 (86.7) | |
ECOG status at study entry, n (%) | <0.001 | |||
PS 0 | 222 (25.3) | 184 (29.6) | 38 (14.9) | |
PS 1 | 432 (49.3) | 299 (48.1) | 133 (52.2) | |
PS 2 | 183 (20.9) | 117 (18.8) | 66 (25.9) | |
PS 3 | 35 (4.0) | 22 (3.5) | 13 (5.1) | |
PS 4 | 5 (0.6) | 0 (0.0) | 5 (2.0) | |
Smoking status, n (%) | 0.056 | |||
Current smoker | 332 (37.9) | 230 (37.0) | 102 (40.0) | |
Former smoker | 441 (50.3) | 308 (49.5) | 133 (52.2) | |
Never smoker | 104 (11.9) | 84 (13.5) | 20 (7.8) | |
PD-L1 expression, n (%) | 0.632 | |||
High (≥50%) | 168 (19.2) | 119 (19.1) | 49 (19.2) | |
Low (≥1% and <50%) | 137 (15.6) | 100 (16.1) | 37 (14.5) | |
Negative (<1%) | 169 (19.3) | 125 (20.1) | 44 (17.3) | |
NA | 403 (46.0) | 278 (44.7) | 125 (49.0) | |
Disease status at study entry, n (%) | <0.001 | |||
Newly diagnosed | 820 (93.5) | 571 (91.8) | 249 (97.6) | |
Recurrent | 55 (6.3) | 50 (8.0) | 5 (2.0) | |
Other | 2 (0.2) | 1 (0.2) | 1 (0.4) | |
Treatment regimen, n (%) | 0.026 | |||
ICI monotherapy | 117 (13.3) | 80 (12.9) | 37 (14.5) | |
ICI+ chemotherapy | 161 (18.4) | 113 (18.2) | 48 (18.8) | |
ICI other combination | 6 (0.7) | 3 (0.5) | 3 (1.2) | |
Pt-based chemotherapy | 392 (44.7) | 284 (45.7) | 108 (42.4) | |
Other chemotherapy | 19 (2.2) | 13 (2.1) | 6 (2.4) | |
TKI | 40 (4.6) | 35 (5.6) | 5 (2.0) | |
Radiation | 32 (3.6) | 25 (4.0) | 7 (2.7) | |
Other active treatment | 16 (1.8) | 14 (2.3) | 2 (0.8) | |
No active treatment | 94 (10.7) | 55 (8.8) | 39 (15.3) |
ECOG, Eastern Cooperative Oncology Group; HIC, host immune classifier; ICI, immune checkpoint inhibition; NA, not available; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1; PS, performance status; Pt, platinum; TKI, tyrosine kinase inhibitor.